Needham & Company LLC Has Lowered Expectations for Cellebrite DI (NASDAQ:CLBT) Stock Price

Posted by Brian Himes on Aug 14th, 2026

Cellebrite DI (NASDAQ:CLBT – Get Free Report) had its price target cut by investment analysts at Needham & Company LLC from $15.00 to $12.50 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 15.74% from the company’s current price.

Other equities research analysts have also issued reports about the stock. DA Davidson raised their price target on shares of Cellebrite DI from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Cellebrite DI presently has an average rating of “Moderate Buy” and a consensus target price of $21.30.

Check Out Our Latest Stock Analysis on Cellebrite DI

Cellebrite DI Stock Performance

Shares of NASDAQ:CLBT opened at $10.80 on Friday. The business’s 50-day simple moving average is $14.52 and its 200 day simple moving average is $14.05. The company has a market cap of $2.69 billion, a P/E ratio of 38.57, a PEG ratio of 1.89 and a beta of 1.18. Cellebrite DI has a one year low of $9.58 and a one year high of $19.98.

Cellebrite DI (NASDAQ:CLBT – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.06. Cellebrite DI had a return on equity of 18.38% and a net margin of 14.48%.The firm had revenue of $131.14 million during the quarter, compared to analysts’ expectations of $131.87 million. Analysts predict that Cellebrite DI will post 0.41 earnings per share for the current year.

Insider Transactions at Cellebrite DI

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the transaction, the executive owned 440,101 shares in the company, valued at approximately $5,620,089.77. The trade was a 2.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO David Barter sold 41,734 shares of the company’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total transaction of $683,602.92. Following the completion of the sale, the chief financial officer directly owned 334,219 shares of the company’s stock, valued at approximately $5,474,507.22. This represents a 11.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 297,934 shares of company stock worth $4,631,972. 5.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cellebrite DI

A number of institutional investors and hedge funds have recently modified their holdings of CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its position in shares of Cellebrite DI by 81.0% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after purchasing an additional 850 shares during the period. CWM LLC lifted its stake in Cellebrite DI by 57.0% in the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after acquiring an additional 889 shares in the last quarter. SkyView Investment Advisors LLC boosted its position in Cellebrite DI by 2.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock worth $597,000 after acquiring an additional 970 shares during the period. Alamea Verwaltungs GmbH boosted its position in Cellebrite DI by 4.3% during the 4th quarter. Alamea Verwaltungs GmbH now owns 24,648 shares of the company’s stock worth $444,000 after acquiring an additional 1,018 shares during the period. Finally, Pacer Advisors Inc. grew its stake in Cellebrite DI by 45.1% during the 4th quarter. Pacer Advisors Inc. now owns 3,981 shares of the company’s stock valued at $72,000 after acquiring an additional 1,238 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI News Summary

Here are the key news stories impacting Cellebrite DI this week:

Positive Sentiment: Cellebrite reported second-quarter adjusted EPS of $0.11, above the $0.05 consensus estimate cited by MarketBeat, while subscription revenue continued to rise. Management also raised its adjusted EBITDA target. Cellebrite second-quarter earnings report
Positive Sentiment: D.A. Davidson maintained its Buy rating, and one analyst argued that the selloff may be excessive relative to Cellebrite’s longer-term growth opportunity. D.A. Davidson rating
Positive Sentiment: Unusual options activity included nearly 20,000 call contracts, substantially above average volume, suggesting some traders were positioning for a rebound, although this is speculative rather than a fundamental catalyst.
Neutral Sentiment: Cellebrite announced a planned CEO succession, with Shiven Ramji replacing Thomas E. Hogan effective August 13. The transition could bring a new strategic direction, but investors may initially view leadership change as an uncertainty. Cellebrite CEO succession announcement
Negative Sentiment: The main pressure came from lowered guidance: third-quarter revenue was projected at $145 million-$148 million versus a $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million fell short of the $568.1 million estimate. The company also lowered its full-year ARR outlook, indicating weaker near-term growth than previously expected. Cellebrite 2026 outlook announcement
Negative Sentiment: Quarterly revenue of $131.14 million slightly missed the $131.87 million estimate, and another earnings estimate placed EPS at $0.11 versus $0.12 expected. The combination of an ARR miss and weaker outlook outweighed the reported EPS beat. Cellebrite investigation notice
Negative Sentiment: Several law firms announced investigations into possible securities-law violations and the accuracy of Cellebrite’s prior projections and disclosures. These are allegations, not findings, but they add legal and reputational risk after the selloff. Kaplan Fox investigation notice
Negative Sentiment: CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, a 15% reduction in his position. Although the sale may be related to the leadership transition or personal financial planning, its timing can weigh on sentiment. SEC insider trading filing

Cellebrite DI Company Profile

(Get Free Report)

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.